Microsoft word - kcentra warfarin -emergent surgery.doc
Warfarin reversal – Emergent Surgery or Invasive Procedure and INR ≥ 2
Authors: Colleen Morton MD, David Dries MD, Gary Collins MD, Michael McGonigal MD Approved: 2/4/2014
To provide guidelines for reversal of Warfarin in a patient who needs an
emergent surgery or invasive procedure and has an INR ≥
(prothrombin complex concentrate, contains plasma-derived Factors II, VII, IX and X) is
given instead of plasma, when there is insufficient time for plasma and vitamin K to
adequately reverse the INR prolongation due to warfarin and where a delay in the
procedure would pose a significant risk of serious morbidity or mortality. Vitamin K is
given to all patients.
Kcentra should not be used for an INR < 2 or to reverse warfarin prior to
non- emergent surgery because of the risk of thrombosis.
The following are guidelines for the reversal of Warfarin in the adult patient (>18
years old) who needs an emergent surgery or invasive procedure (in < 24 hours, per FDA
approval), with an INR ≥ 2, and where we do not have enough time for plasma and vitamin K
to adequately reverse the INR
Confirm that the patient is on warfarin.
Obtain CBC and platelet count, creatinine, type and cross, and INR.
IF THE PATIENT HAS AN INR ≥ 2 AND NEEDS AN EMERGENT SURGERY OR INVASIVE
1. Kcentra (prothrombin complex concentrate, contains plasma-derived Factors II, VII, IX
and X) - one dose only, in Units of Factor IX /kg.
Dose based on body weight up to, but not exceeding 100kg.
Vitamin K 10 mg IV (dilute in NS or D5W and give slowly over 30 minutes.) Monitor
for anaphylaxis. – use this dose if the patient will not require warfarin
anticoagulation soon after surgery and bleeding risks are high.
Vitamin K 2.5 - 5 mg IV (dilute in NS or D5W and give slowly over 30 minutes.)
Monitor for anaphylaxis. – use this dose if the patient is high risk for thrombosis
and will require warfarin anticoagulation soon after surgery.
Contraindications to use of Kcentra for Warfarin reversal
Kcentra should not be for an INR < 2, non-emergent surgery or high risk of thrombosis
Disseminated intravascular coagulopathy (DIC)
History of heparin induced thrombocytopenia ( HIT)
Kcentra increases the risk of arterial and venous thrombosis.
There is no data on the use of Kcentra in patients with the following conditions. Patients with these conditions were excluded from the study used for FDA approval of Kcentra for warfarin reversal. Caution is advised: - Arterial or venous thrombosis within 3 months - TIA or unstable angina within 3 months - Critical aortic stenosis -Severe peripheral vascular disease - Known antiphospholipid antibody syndrome
Follow up labs INR Goal is ≤ 1.5 INR should be checked 30 minutes after giving Kcentra If INR still > 1.5 give plasma 15 ml/kg IV
: Patients, on warfarin, who also have liver disease may have deficiencies of more than just the vitamin K-dependent clotting factors. In this situation Kcentra (which replaces only FII, VII, IX and X) may not adequately reverse the INR. These patients may need plasma in addition to Kcentra.
Curriculum Vitae David E. Ross, M.D. Narrative summary Dr. Ross is the director of the Virginia Institute of Neuropsychiatry and clinical assistant professor at Virginia Commonwealth University (VCU). He completed medical school and residency in psychiatry at VCU. After that, he finished a fel owship in neuropsychiatry at the Maryland Psychiatric Research Center, University of Mar
Effective January 1, 2012 2012 EMPIRE PLAN FLEXIBLE FORMULARY Administered by UnitedHealthcare The following is a list of the most commonly prescribed generic and brand-name drugs included on the 2012 Empire Plan Flexible Formulary. This is not a complete list of all prescription drugs on the flexible formulary or covered under The Empire Plan. This list and excluded medications are